People: Navidea Biopharmaceuticals Inc (NAVB.K)

NAVB.K on American Stock Exchange

1.48USD
28 Apr 2015
Change (% chg)

$-0.04 (-2.32%)
Prev Close
$1.51
Open
$1.51
Day's High
$1.51
Day's Low
$1.46
Volume
49,371
Avg. Vol
520,531
52-wk High
$2.02
52-wk Low
$0.97

Search Stocks

Tulip, Thomas 

Dr. Thomas H. Tulip, Ph.D. has been appointed as Chief Business Officer in December 2014. Prior to joining Navidea, Dr. Tulip held senior leadership positions at Alseres Pharmaceuticals, Lantheus Medical Imaging, Bristol Myers Squibb (BMS) and DuPont, where his roles spanned product discovery and development, business and technology planning, brand and alliance management and international business management. Most recently, as President, Alseres Molecular Imaging, Dr. Tulip led efforts to develop markets for a Phase III neuroimaging agent. While at DuPont and BMS, he was instrumental in the development, commercialization and international management of the highly successful nuclear cardiology franchise, successfully built the BMS Medical Imaging international business, and led planning activities for innovative PET tracers at Lantheus/BMS. Dr. Tulip earned a B.S. from the University of Vermont, and an M.S. and Ph.D. from Northwestern University. He was a visiting scholar at Osaka University and served as adjunct professor at Northeastern University. Dr. Tulip serves on the board of directors of the Medical Imaging Technology Association (MITA) and leads its PET Working Group in the Molecular Imaging Section. He was recently Chairperson of the Institute for Molecular Technologies (IMT) and held numerous leadership positions there. He served on the Board of the Academy of Molecular Imaging, including as its Treasurer. Dr. Tulip was Chairperson for the Society of Nuclear Medicine (SNM) Corporate Advisory Board and has been active in a number of Council on Radionuclides and Radiopharmaceuticals (CORAR) committees, now serving on its Board of Directors.

Basic Compensation

Total Annual Compensation, USD Long-Term Incentive Plans, USD All Other, USD Fiscal Year Total, USD
314,000 -- 168,681 482,681

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Gordon Troup

--

Ricardo Gonzalez

850,699

Brent Larson

401,045

Frederick Cope

429,370

William Regan

--

Thomas Klima

--
As Of  30 Dec 2014
Search Stocks